Varda pockets $251m to back space-based pharma processing mission - Pharmaceutical Technology

Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines. Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines. Varda hopes to market the first drug produced in space. Credit: buradaki / Shutterstock.com. Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the industry increasingly recognises the potential of producing drugs in microgravity conditions. With cash provided by Lux Capital and Natural Capital, as well as contributions from other players like Khosla Ventures…

Source: Pharmaceutical Technology